A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)
Sponsor: H. Lundbeck A/S
Listed as NCT02509793, this PHASE4 trial focuses on Huntington's Disease and remains ongoing. Sponsored by H. Lundbeck A/S, it has been updated 14 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Oct 2024 — Present [monthly]
Unknown PHASE4
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE4
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE4
▶ Show 9 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE4
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE4
-
Dec 2018 — Oct 2019 [monthly]
Recruiting PHASE4
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Aug 2017 — Sep 2017 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lundbeck A/S
- William Ondo, MD
For direct contact, visit the study record on ClinicalTrials.gov .